11 December 2020
An Artificial Intelligence test has been shown to be able to rapidly screen patients arriving in Emergency Departments for COVID-19, using clinical information routinely available within the first hour of coming to hospital.
Results of the CURIAL study, published today in The Lancet Digital Health, show that the AI test correctly predicted the COVID-19 status of 92.3% of patients coming to Emergency departments at the John Radcliffe Hospital in Oxford and the Horton General Hospital in Banbury during a two-week test period. Compared against results of laboratory swab testing, the CURIAL AI screening test correctly ruled-out COVID-19 97.6% of the time. However, whereas swab testing typically takes 24 hours, the AI screening test offers rapid results using data that is already routinely available within one hour.
The screening test was developed by infectious disease and clinical machine learning experts at the University of Oxford. The research team is led by Dr Andrew Soltan, an NIHR Academic Clinical Fellow (Cardiology) at the John Radcliffe Hospital, joining with the AI for Healthcare lab of Professor David Clifton, within Oxford’s Institute of Biomedical Engineering, and with Professor David Eyre of the Oxford Big Data Institute.
Dr Andrew Soltan, also a researcher at Oxford University’s Radcliffe Department of Medicine, said: ‘Every day around 350 people come to our Emergency Departments in the John Radcliffe Hospital in Oxford and the Horton General Hospital in Banbury, yet only a small number will be ill with COVID-19. The CURIAL AI test offers clinical teams the potential to rapidly and confidently rule-out a diagnosis of COVID-19 for a large majority of the patients who do not have the infection, while identifying patients at higher risk of testing positive. The higher-risk patients can then be cared for in clinical areas with additional infection-control precautions while swab test results are awaited.’
The researchers developed the AI screening test using routine healthcare data (blood tests and vital signs) extracted from electronic health records for 115,394 patients and 72,310 admissions.
Once developed, the two screening models were applied to all patients presenting or admitted to the John Radcliffe Hospital in Oxford and the Horton General Hospital in Banbury. The CURIAL AI model, screening for COVID-19 in all patients coming to the Emergency departments, was found to be 92.3% accurate when compared to the PCR test, while a specific model for patients admitted to the hospitals was 92.5% accurate. The models correctly excluded COVID-19 97.6% of the time for patients coming to ED, and 97.7% of the time for the patients admitted.
The CURIAL screening test is therefore optimised to quickly give negative results with high confidence, safely excluding COVID-19 at the front door, and maintaining flow through the hospital.
Dr Soltan said: ‘The turnaround time for COVID-19 swabs has come down since the start of the pandemic. However, until we have confirmation that patients are negative we must take additional precautions for patients with coronavirus symptoms, which are very common as we head in to winter. Patients screened by the AI test as low-risk could benefit from reduced delays to their care if we know sooner that they do not have COVID-19.
‘A strength of our AI test is that it fits within the existing clinical care pathway and works with existing lab equipment. This means scaling it up will be relatively fast and cheap.’
Dr Ravi Pattanshetty, an A&E Consultant at the John Radcliffe Hospital supporting translation of the CURIAL into Emergency Departments, said: ‘The John Radcliffe Emergency Department will be conducting prospective validation of this AI tool in the coming months. We will be mainly using it to triage patients at the front door to help the flow of patients into various designated areas. We are very excited at the prospect of being able to use a tool which, should it prove successful, will help hospitals make more informed and rapid decisions with regards to patient flow. It has the potential to be tailored to be used in various scenarios.’
The researchers have now received an award from the University Medical and Life Sciences Translational Fund, comprising devolved funding from the Medical Research Council and Wellcome Trust, and are working with Infectious Diseases and Emergency Department teams at the John Radcliffe Hospital to trial the CURIAL AI test in the clinical pathway. A collaboration with University Hospitals Birmingham will allow the team to validate the AI test’s performance using data from a different NHS organisation.
The team are also validating a version of the CURIAL AI test that uses near-patient blood tests that can be performed in 10 minutes, reducing the time the AI needs to exclude coronavirus infection from one hour to only minutes. A trial to evaluate the near-patient AI screening model, named CURIAL-Rapide, is expected to begin shortly at the John Radcliffe Hospital in Oxford.
David Clifton, Professor of Clinical Machine Learning at the Department of Engineering Science, said: ‘With many of our clinical colleagues working on the front lines to fight COVID-19, data scientists in Healthcare AI have a supporting role to play by constructing tools to help care for patients. The unique ecosystem at Oxford between hospitals and clinical AI teams gives us a great opportunity to contribute to the international effort against COVID-19.
‘This project is a great example of what can be done, and at very great pace, to fast-track the development of technologies to help in the current pandemic – and to increase the resilience of the country’s healthcare system for any future events.’
Notes to editors:
For further information and interviews, please contact: firstname.lastname@example.org or call 01865 280528.
Read the paper once the embargo lifts here: http://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30274-0/fulltext
DOI address: https://doi.org/10.1016/S2589-7500(20)30274-0
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
Oxford University Hospitals NHS Foundation Trust (OUH) is one of the largest acute teaching trusts in the UK, with a national and international reputation for the excellence of its services and its role in patient care, teaching and research. The Trust supports world-leading research programmes in cardiovascular diseases, musculoskeletal disorders, neurological disorders such as Parkinson’s and Alzheimer’s through its designation as one of the UK’s five comprehensive biomedical centres. It works in close partnership with the University of Oxford and is a leading centre for cancer, neurosciences, diabetes, genetics and many other fields. Research themes of particular strength are: cancer, cardiovascular science, diabetes, endocrinology and metabolism, infection and immunology, musculoskeletal science, neuroscience and reproduction and development. This brings together academic research expertise with clinical teams to translate medical science into better healthcare treatments. Our patients benefit from world-class discovery and innovation supported by the NIHR Oxford Biomedical Research Centre, a partnership between the Trust and the University of Oxford, funded by the National Institute for Health Research. The Trust employs over 12,000 staff and consists of four hospitals: the Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in Oxford and the Horton General Hospital in Banbury. On 1 October 2015 the Trust was awarded Foundation status and became Oxford University Hospitals NHS Foundation Trust. www.ouh.nhs.uk
About the Big Data Institute
The Big Data Institute (BDI) is an interdisciplinary research institute that focuses on the analysis of large, complex, heterogeneous data sets for research into the causes and consequences, prevention and treatment of disease. Big Data methods are transforming the scale (breadth, depth and duration) and efficiency (data accumulation, storage, processing and dissemination) of large-scale clinical research. The work of the BDI requires people and projects that span traditional departmental boundaries and scientific disciplines, supported by technical resources to handle the vast quantities of data they generate. www.bdi.ox.ac.uk